Thus, targeting of SCARB1 by HDL NPs with reduction of cell cholesterol uptake and compensatory increase in de novo cholesterol biosynthesis is a potential translational model for treatment of cholesterol uptake–dependent lymphoma. This evidence concerns the gene SCARB1 and lymphoma.